Peter J. Gardner, Colleen Loynachan, Tsepo L. Tsekoa, Lindsay Keir, Vijay Yabannavar, Erin Sparrow
{"title":"制造创新对于单克隆抗体的可负担性和可及性至关重要","authors":"Peter J. Gardner, Colleen Loynachan, Tsepo L. Tsekoa, Lindsay Keir, Vijay Yabannavar, Erin Sparrow","doi":"10.1038/s44222-025-00301-w","DOIUrl":null,"url":null,"abstract":"Biopharmaceutical manufacturing innovation is essential for making monoclonal antibodies affordable and accessible by overcoming critical cost and supply barriers. Importantly, innovation supporting regional production will be required to meet low- and middle-income country health needs and strengthen global resilience against future infectious disease outbreaks.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"3 6","pages":"438-440"},"PeriodicalIF":37.6000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Manufacturing innovation is essential for monoclonal antibody affordability and access\",\"authors\":\"Peter J. Gardner, Colleen Loynachan, Tsepo L. Tsekoa, Lindsay Keir, Vijay Yabannavar, Erin Sparrow\",\"doi\":\"10.1038/s44222-025-00301-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biopharmaceutical manufacturing innovation is essential for making monoclonal antibodies affordable and accessible by overcoming critical cost and supply barriers. Importantly, innovation supporting regional production will be required to meet low- and middle-income country health needs and strengthen global resilience against future infectious disease outbreaks.\",\"PeriodicalId\":74248,\"journal\":{\"name\":\"Nature reviews bioengineering\",\"volume\":\"3 6\",\"pages\":\"438-440\"},\"PeriodicalIF\":37.6000,\"publicationDate\":\"2025-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature reviews bioengineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44222-025-00301-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature reviews bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44222-025-00301-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Manufacturing innovation is essential for monoclonal antibody affordability and access
Biopharmaceutical manufacturing innovation is essential for making monoclonal antibodies affordable and accessible by overcoming critical cost and supply barriers. Importantly, innovation supporting regional production will be required to meet low- and middle-income country health needs and strengthen global resilience against future infectious disease outbreaks.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
